Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIB-626 (NMN) with and without high-intensity exercise in highly fit young adults
NCT05878119Phase 2Completed
- Sponsor
- Metro International Biotech
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal β-nicotinamide mononucleotide (4 arms), sponsored by Metro International Biotech. Primary endpoint: Aerobic capacity (VO2 max) at 11 weeks. Started Oct 2023; status: completed.
02
Drugs
liposomal β-nicotinamide mononucleotide
Beyond the preview
Go deeper on NCT05878119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878119.